Current Diabetes Reports

, Volume 6, Issue 1, pp 47–54

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes

  • Susanne Trost
  • Richard E. Pratley
  • Burton E. Sobel
Article

DOI: 10.1007/s11892-006-0052-5

Cite this article as:
Trost, S., Pratley, R.E. & Sobel, B.E. Curr Diab Rep (2006) 6: 47. doi:10.1007/s11892-006-0052-5
  • 75 Downloads

Abstract

Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome.

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  • Susanne Trost
    • 1
  • Richard E. Pratley
  • Burton E. Sobel
  1. 1.Diabetes and Metabolism Translational Medicine UnitUniversity of Vermont College of MedicineBurlingtonUSA

Personalised recommendations